Research programme: neuropathic pain therpaeutic - Jeil Pharmaceuticals
Latest Information Update: 21 Mar 2016
At a glance
- Originator Jeil Pharmaceutical
- Class Analgesics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Neuropathic pain
Most Recent Events
- 21 Mar 2016 Early research in Neuropathic pain in South Korea prior to March 2016 (unspecified route)